Autres langues ViroGates A/S

Actions

VIRO

DK0061030574

Temps Différé Nasdaq Copenhagen Autres places de cotation 16:59:52 26/04/2024			Varia. 5j.	Varia. 1 janv.
6,5 ^DKK	-11,92%		+8,33%	+7,97%

15/04	Virogates A/S annonce le résultat de son dépôt de demande d'homologation pour le latex Sobi® ? Turbi Latex auprès de la Food and Drug Administration américaine	CI
21/03	ViroGates A/S publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Resolutions from the Annual General Meeting of ViroGates A/S	25/04
ViroGates announces the outcome of its Q-Submission filing for suPARnostic® TurbiLatex with the US FDA and the overall timeline for filing a submission of a 510k/“De Novo” application with the FDA	15/04
Virogates A/S Announces the Outcome of Its Q-Submission Filing for Sobi®? Turbi Latex with the Us Food and Drug Administration	15/04
ViroGates gives notice to convene the Annual General Meeting on 25 April 2024	10/04
ViroGates announces its Annual Report 2023: Revenue was affected by the loss of COVID-19 customers and a difficult transition into general triage	21/03
ViroGates A/S Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Subscription of shares by majority shareholder in relation to the recently completed rights emission in ViroGates A/S	21/12
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	21/12
ViroGates publishes its financial calendar for 2024	21/12
ViroGates announces financial guidance for 2024	21/12
ViroGates A/S Provides Earnings Guidance for the Year 2024	21/12
ViroGates' capital raise of DKK 13.9 million and issue of 3,097,047 new shares have been registered	19/12
ViroGates announces the outcome of its rights issue	15/12
ViroGates A/S : Most interesting suPAR studies of 2023	08/12
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19	07/12
ViroGates A/S : Clinical role of suPAR in the prognosis of patients in the emergency setting and its influence on risk stratification	06/12
The subscription period in ViroGates’ rights issue begins today	30/11
Resolutions from the Extraordinary General Meeting of ViroGates A/S	24/11
ViroGates A/S : Social isolation in mid-adulthood is associated with elevated suPAR	23/11
ViroGates gives notice to convene an Extraordinary General Meeting on 24 November 2023	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues ViroGates A/S

Actions

VIRO

DK0061030574

Autres langues

Filtres